NeurologyLive® Friday 5 — October 9, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!

Click the read more or watch now buttons for more details and information about each highlight.

1: Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient

In a recent MDS 2026 Q&A, Hubert Fernandez, MD, the director of the Center for Neurological Restoration and Head of Movement Disorders at Cleveland Clinic, discussed the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease.

2: Validating an African Ancestry–Linked GBA1 Risk Variant in PD GENEration: Kamalini Galvelis, MS

In a recent MDS 2026 video interview, Kamalini Galvelis, MS, the associate vice president of clinical research at the Parkinson's Foundation, discussed new PD GENEration data validating a GBA1 intronic risk variant for Parkinson disease. [WATCH TIME: 6 minutes]

3: Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA

In a recent MDS 2026 Q&A, Benjamin Walter, MD, MBA, the section head of movement disorders and medical director of the Deep Brain Stimulation Program at Cleveland Clinic, discussed how advances in biomarker testing and genetic characterization are informing Parkinson disease care.

4: New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease

In a recent Q&A, Carlos Cruchaga, PhD, the director of the NeuroGenomics and Informatics Center at Washington University, discussed emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

5: Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis

In a recent Q&A interview, Christen Kutz, PhD, PA-C, an experienced neurology physician assistant, discussed a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.